Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesLoans and Notes ReceivablesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares OutstandingShares Outstanding
Ratios

Zhengye Biotechnology Holding (ZYBT) Loans and Notes Receivables (2023 - 2025)

Zhengye Biotechnology Holding has reported Loans and Notes Receivables over the past 3 years, most recently at -$14000.0 for Q2 2025.

  • Quarterly Loans and Notes Receivables changed N/A to -$14000.0 in Q2 2025 from the year-ago period, while the trailing twelve-month figure was -$14000.0 through Jun 2025, changed N/A year-over-year, with the annual reading at $3.5 million for FY2024, 8.74% up from the prior year.
  • Loans and Notes Receivables was -$14000.0 for Q2 2025 at Zhengye Biotechnology Holding, down from $3.6 million in the prior quarter.
  • Over five years, Loans and Notes Receivables peaked at $3.6 million in Q4 2024 and troughed at -$14000.0 in Q2 2025.
  • The 3-year median for Loans and Notes Receivables is $3.2 million (2023), against an average of $2.3 million.
  • The largest YoY upside for Loans and Notes Receivables was 10.5% in 2024 against a maximum downside of 10.5% in 2024.
  • A 3-year view of Loans and Notes Receivables shows it stood at $3.2 million in 2023, then grew by 10.5% to $3.6 million in 2024, then plummeted by 100.39% to -$14000.0 in 2025.
  • Per Business Quant, the three most recent readings for ZYBT's Loans and Notes Receivables are -$14000.0 (Q2 2025), $3.6 million (Q4 2024), and $3.2 million (Q4 2023).